JAMA Neurology presents an RCT on stroke prevention in atrial fibrillation. Study details: 187 men, 62 women, mean age 71.7 years. Interventions: 249 patients split into standard therapy(124) and ablation(125). Findings show similar rates between groups.

In patients with atrial fibrillation and recent stroke, adding catheter ablation to oral anticoagulation did not significantly reduce recurrent stroke, systemic embolism, death, or hospitalization for heart failure compared to standard therapy. ja.ma/4te51q4

Four graphs show 'PrimeC' and 'Placebo' effects over time. Graph A: NFL geometric mean ratio to baseline, with GMR@1. 99 and GMR@2. 91 labels. Graph B: Ferritin mean concentration. Graph C: Transferrin mean concentration levels. Graph D: miRNA differential expression.

PrimeC demonstrated comparable safety to placebo and showed slowed functional decline, reduced ALS-related complications, and modulation of iron-regulatory and microRNA biomarkers in adults with #ALS over 18 months of treatment.

ja.ma/4lXjuE2

Figure 1. Patient's left eye changes in sclera pre- and post-surgery. Image A: Scleral hyperemia before surgery. Image B: Marked reduction in scleral hyperemia after surgery.

#CavernousSinus dural arteriovenous fistula can present with proptosis, conjunctival injection, and ophthalmoplegia; endovascular embolization achieved complete occlusion and rapid symptom resolution in this case.

ja.ma/3QFU95P

Four line graphs show cognitive composite z-scores over 24 months, comparing exercise vs. no exercise and IRVR vs. no IRVR for PACC and NIHTB-CB. Participant numbers are listed for each group at each time point.

Aerobic exercise, intensive blood pressure and cholesterol reduction, or both did not show differences in cognitive function improvement over 24 months among older adults with family history of #dementia or subjective #cognitive decline.

ja.ma/4m2irCI

JAMA Neurology editorial: Beyond Recurrence—Late Effects of Chronic Subdural Hematoma. By David J. Robinson, MD, MS@1; Jared Knopman, MD@2. Published Online: April 13, 2026. doi: 10.1001/jamaneurol.2026.0655.

💬Editorial: Decade-long follow-up highlights that patients with surgically treated #ChronicSubduralHematoma have persistent excess mortality and long-term cognitive and functional impairment, even when overall quality of life appears preserved.

ja.ma/4sy8heK

Forest plot shows change in body mass index and smoking among people with multiple sclerosis between 1990-2020. Outcomes: underweight 1.028 (1.023-1.033), normal weight 1 [Reference], overweight 0.990 (0.988-0.992), obese 1.045 (1.042-1.048), etc.

#MultipleSclerosis prevalence in England more than doubled in 30 years as survival improved, but abnormal weight, tobacco use, and deprivation gradients persisted and were associated with increased mortality risk.

ja.ma/4toLtyP

Forest plot shows change in body mass index and smoking among people with multiple sclerosis between 1990-2020. Outcomes: underweight 1.028 (1.023-1.033), normal weight 1 [Reference], overweight 0.990 (0.988-0.992), obese 1.045 (1.042-1.048), etc.

#MultipleSclerosis prevalence in England more than doubled in 30 years as survival improved, but abnormal weight, tobacco use, and deprivation gradients persisted and were associated with increased mortality risk.

ja.ma/4v4WGX0

Four graphs show 'PrimeC' and 'Placebo' effects over time. Graph A: NFL geometric mean ratio to baseline, with GMR@1. 99 and GMR@2. 91 labels. Graph B: Ferritin mean concentration. Graph C: Transferrin mean concentration levels. Graph D: miRNA differential expression.

PrimeC demonstrated comparable safety to placebo and showed slowed functional decline, reduced ALS-related complications, and modulation of iron-regulatory and microRNA biomarkers in adults with #ALS over 18 months of treatment.

ja.ma/3ObSGDw

JAMA Neurology research letter, "Interstitial Lung Disease as a Late Occurrence in Ocrelizumab-Treated Patients With Multiple Sclerosis" by Anna E. Zurawska, Anne H. Cross, and Katarzyna Rzeszutek. Published online April 6, 2026.

Among patients with multiple sclerosis treated long-term with ocrelizumab, interstitial lung disease developed after a mean of 10.5 years, mainly as organizing pneumonia with variable outcomes.

ja.ma/4ccnX1h

Four line graphs show cognitive composite z-scores over 24 months, comparing exercise vs. no exercise and IRVR vs. no IRVR for PACC and NIHTB-CB. Participant numbers are listed for each group at each time point.

Aerobic exercise, intensive blood pressure and cholesterol reduction, or both did not show differences in cognitive function improvement over 24 months among older adults with family history of #dementia or subjective #cognitive decline.

ja.ma/4c1CwES

Map of Germany showing telemedicine network distribution, featuring cities like Berlin, Munich, and Dresden. Network centers such as ANNOTeM, FAST, SOS-TeleNET, and TEMPIS are indicated with colored markers, sized by patient enrollment numbers from 1-90.

In a multicenter German study, teleneurological ward rounds in subacute #Stroke care were noninferior and showed greater guideline adherence across all quality domains compared with on-site ward rounds, especially in secondary prevention.

ja.ma/4e4gnrY

Four line graphs show cognitive composite z-scores over 24 months, comparing exercise vs. no exercise and IRVR vs. no IRVR for PACC and NIHTB-CB. Participant numbers are listed for each group at each time point.

Aerobic exercise, intensive blood pressure and cholesterol reduction, or both did not show differences in cognitive function improvement over 24 months among older adults with family history of #dementia or subjective #cognitive decline.

ja.ma/4sRM7VY

Forest plot shows change in body mass index and smoking among people with multiple sclerosis between 1990-2020. Outcomes: underweight 1.028 (1.023-1.033), normal weight 1 [Reference], overweight 0.990 (0.988-0.992), obese 1.045 (1.042-1.048), etc.

#MultipleSclerosis prevalence in England more than doubled in 30 years as survival improved, but abnormal weight, tobacco use, and deprivation gradients persisted and were associated with increased mortality risk.

ja.ma/48qZW5l

Figure 2. Distribution of Scores on the Modified Rankin Scale at 90 Days. Two horizontal bar graphs compare 'Delayed extubation (n=86)' and 'Early extubation (n=85)' across Modified Rankin Scale scores 0-6. Percentages for each score are noted on the bars.

Among patients undergoing endovascular #thrombectomy for acute #Stroke, early (<6 hours) vs delayed (6–12 hours) extubation did not improve 90-day functional independence, hospital stay, complication rates, or mortality.

ja.ma/4vlyboX

Among patients undergoing endovascular #thrombectomy for acute #Stroke, early (<6 hours) vs delayed (6–12 hours) extubation did not improve 90-day functional independence, hospital stay, complication rates, or mortality. ja.ma/4taKNgE

Four graphs show 'PrimeC' and 'Placebo' effects over time. Graph A: NFL geometric mean ratio to baseline, with GMR@1. 99 and GMR@2. 91 labels. Graph B: Ferritin mean concentration. Graph C: Transferrin mean concentration levels. Graph D: miRNA differential expression.

PrimeC demonstrated comparable safety to placebo and showed slowed functional decline, reduced ALS-related complications, and modulation of iron-regulatory and microRNA biomarkers in adults with #ALS over 18 months of treatment.

ja.ma/4m3oRBI

JAMA Neurology editorial titled 'Signal, Speculation, and Standards of Proof in latrogenic Alzheimer Disease' by Brian S. Appleby, MD@1,2,3,4; Mark L. Cohen, MD@1,2,3. Published Online: March 30, 2026. doi: 10.1001/jamaneurol.2026.0421.

💬 Editorial: Current evidence supports iatrogenic transmission of cerebral amyloid angiopathy but not #AlzheimerDisease; a definitive causal link between contaminated growth hormone exposure and AD remains speculative.

ja.ma/3NSFPpM

Figure 3. MRI head scans from 3 cadaveric pituitary-derived human growth hormone recipients with dementia syndromes. A) Symptom onset at age 56 y; coronal T2-weighted image age 61 y. B) Symptom onset at age 60 y; coronal T1-weighted image age 67 y. C) Symptom onset at age 58 y; coronal T1-weighted image age 63 y.

Patients treated with cadaveric pituitary-derived human growth hormone contaminated with amyloid-β developed early-onset #AlzheimerDisease with prominent language deficits and histopathological features consistent with AD.

ja.ma/4cdaqYk

Forest plot shows change in body mass index and smoking among people with multiple sclerosis between 1990-2020. Outcomes: underweight 1.028 (1.023-1.033), normal weight 1 [Reference], overweight 0.990 (0.988-0.992), obese 1.045 (1.042-1.048), etc.

#MultipleSclerosis prevalence in England more than doubled in 30 years as survival improved, but abnormal weight, tobacco use, and deprivation gradients persisted and were associated with increased mortality risk.

ja.ma/4sqZYSR

JAMA Neurology editorial: "Tilting at Treadmills—Pitfalls and Potential of Dementia Prevention Trials" by Holly Elser, MD, PhD1,2; Jonathan Graff-Radford, MD1,3. Published Online: March 23, 2026. doi: 10.1001/jamaneurol.2026.0370

💬 Editorial: In a randomized trial, aerobic exercise and intensive vascular risk reduction for older adults at risk of #dementia led to only modest cognitive improvement, with no significant group differences in global cognitive function.

ja.ma/3NVnMPI

Four line graphs show cognitive composite z-scores over 24 months, comparing exercise vs. no exercise and IRVR vs. no IRVR for PACC and NIHTB-CB. Participant numbers are listed for each group at each time point.

Aerobic exercise, intensive blood pressure and cholesterol reduction, or both did not show differences in cognitive function improvement over 24 months among older adults with family history of #dementia or subjective #cognitive decline.

ja.ma/40Uzey1

JAMA Neurology presents: "RCT: Tavapadon as Adjunctive Treatment for Parkinson Disease." Study highlights: 321 male, 186 female patients; intervention with 245 placebo & 242 Tavapadon doses. Graph: Tavapadon group shows increase in daily 'good-on-time'.

In adults with #ParkinsonDisease experiencing motor fluctuations on levodopa, adjunctive tavapadon increased daily good-on-time and decreased daily off-time compared to placebo, with a favorable safety profile.

ja.ma/4d8iqLo

JAMA Neurology presents RCT: Fixed-Dose Tavapadon for Early Parkinson Disease. Population: 342 Male, 187 Female. Intervention: 529 participants randomized. Findings: Tavapadon(5mg & 15mg) showed statistically significant improvement compared to placebo.

Among adults with early #ParkinsonDisease, fixed-dose tavapadon (5 or 15 mg once daily) improved motor function over 26 weeks versus placebo, with most adverse events mild or moderate in severity.

ja.ma/4bxJDWE

Kaplan-Meier estimation shows the cumulative incidence of relapse after stopping treatment. The y-axis displays 'Relapse-free probability,' while the x-axis represents 'Time since treatment discontinuation, y.' Numbers at risk are noted at time intervals.

Among adult patients with #MOGAD, discontinuation of oral immunosuppressants or rituximab was associated with a low 1-year relapse risk, especially after ≥1 year of treatment and ≥2 years since last relapse.

ja.ma/40RZLvS

JAMA Neurology editorial: "Tilting at Treadmills—Pitfalls and Potential of Dementia Prevention Trials" by Holly Elser, MD, PhD@1,2; Jonathan Graff-Radford, MD@1,3. Published Online: March 23, 2026. doi: 10.1001/jamaneurol.2026.0370

💬 Editorial: In a randomized trial, aerobic exercise and intensive vascular risk reduction for older adults at risk of #dementia led to only modest cognitive improvement, with no significant group differences in global cognitive function.

ja.ma/4uNkHSi

Four line graphs show cognitive composite z-scores over 24 months, comparing exercise vs. no exercise and IRVR vs. no IRVR for PACC and NIHTB-CB. Participant numbers are listed for each group at each time point.

Aerobic exercise, intensive blood pressure and cholesterol reduction, or both did not show differences in cognitive function improvement over 24 months among older adults with family history of #dementia or subjective #cognitive decline.

ja.ma/4byg8UE

Forest plot shows change in body mass index and smoking among people with multiple sclerosis between 1990-2020. Outcomes: underweight 1.028 (1.023-1.033), normal weight 1 [Reference], overweight 0.990 (0.988-0.992), obese 1.045 (1.042-1.048), etc.

#MultipleSclerosis prevalence in England more than doubled in 30 years as survival improved, but abnormal weight, tobacco use, and deprivation gradients persisted and were associated with increased mortality risk.

ja.ma/4bJxsEJ

Kaplan-Meier estimation shows the cumulative incidence of relapse after stopping treatment. The y-axis displays 'Relapse-free probability,' while the x-axis represents 'Time since treatment discontinuation, y.' Numbers at risk are noted at time intervals.

Among adult patients with #MOGAD, discontinuation of oral immunosuppressants or rituximab was associated with a low 1-year relapse risk, especially after ≥1 year of treatment and ≥2 years since last relapse.

ja.ma/4c5t1W8

JAMA Neurology presents: "RCT: Tavapadon as Adjunctive Treatment for Parkinson Disease." Study highlights: 321 male, 186 female patients; intervention with 245 placebo & 242 Tavapadon doses. Graph: Tavapadon group shows increase in daily 'good-on-time'.

In adults with #ParkinsonDisease experiencing motor fluctuations on levodopa, adjunctive tavapadon increased daily good-on-time and decreased daily off-time compared to placebo, with a favorable safety profile.

ja.ma/4bJXiZr

JAMA Neurology editorial: "Tilting at Treadmills—Pitfalls and Potential of Dementia Prevention Trials" by Holly Elser, MD, PhD@1,2; Jonathan Graff-Radford, MD@1,3. Published Online: March 23, 2026. doi: 10.1001/jamaneurol.2026.0370

💬 Editorial: In a randomized trial, aerobic exercise and intensive vascular risk reduction for older adults at risk of #dementia led to only modest cognitive improvement, with no significant group differences in global cognitive function.

ja.ma/4sDYd52